## SUPPLEMENTARY MATERIAL

**Supplementary file 2.** Cases are Split per elicitor groups as included in IAR. NSAID: Non-steroid antiinflamatory drug. Severity scales: CJS: Clinical Judgment Scale (1-10) Median (P25-P75); RMS: Ring Messmer scale. MW: Man Whitney test; Chi2: Chi Square test; CRD: Component determinations and number of performed tests; neg: negative result; pos: positive result. Date: year of inclusion in IAR (number of cases).

		ELICITOR GROUP							
		DRUGS 26 (22.4%)	FOODS 72 (62.1%)	HYMENOPTERA 9 (7.8%)	IDIOPATHIC 4 (3.4%)	OTHERS 3 (2.6%)	DIFFERENT ELICITOR GROUPS 2 (1.7%)	Comparisons	
AGE	MEDIAN (P25-75)	59.9 (52-70)	29 (12.2-44-75)	58 (46.5-66-5)	52 (32.2-62)	46 (14-52)	68.5 (68-69)	0.0001 (MW)	
GENDER	Female Male	57.7% 42.3%	55.6% 44.4%	33.3% 66.7%	50% 50%	66.7% 33.3%	100%		
ELICITORS	Number of cases	Betalactams: 10 (38.4%) NSAID: 6 (23.1%) Contrast Media: 4 (15.3%) Quinolone: 4 (15.3%) Local anesthetic: 1 (3.8%) Sugammadex: 1 (3.8%)	Nuts/ Tree nuts: 16 (22.2%) Fruits: 14 (19.4%) Vegetables: 4 (5.5%) Grains: 3 (4.1%) Animal foods 20 (27.7%) Legumes 8 (11.1%) Seeds 1 (1.38%) Simultaneous food groups intake 6 (8.33%)	Honey bee: 2 (22.2%) Polistes: 5 (55.6%) Vespula: 2 (22.2%)		Royal Jelly: 1 (33.3%) Anisakis simplex: 2 (66.6%)	Tick bite and pork meat: 1 (50%) Tick bite and peach: 1 (50%)		
COFACTORS	Number of cases (% of cases with any cofactor)	Drugs: 21 Stress likely: 8 Menstruation: 1	Drugs: 18 Exercise: 19 Alcohol: 10 Menstruation: 1	Drugs 6 Exercise 2 Alcohol 1	Drugs: 3 Exercise: 1 Alcohol: 1	Absent 100%	Drugs: 2 Exercise: 1 Alcohol: 2	0.003 (Chi2)	
SEVERITY	CJS Md (P25- P75)	8 (7-8.5)	7 (7-8)	8.5 (7.5-8.75)	7.75 (6.75-8)	7.5 (7.5-)	7	0.014 (MW)	
	RMS (I,II,III,IV)	II: 34.6% III: 61.5% IV: 3.8%	II: 56.9% III: 43.1%	III: 100%	II: 50% III: 50%	III: 100%	П: 100%	0.001 (Chi2)	
CRD	SPT	7 (26.9%) (neg 6; pos 1)	69 (95.8%) (neg 32; pos 37)	0	4 (100%) (neg 4; pos 0)	1 (33.3%) (neg 1; pos 0)	1 (50%) (neg 1; pos 0)		
	Uniplex	0	56 (77.7%) (neg 15; pos 41)	4 (44.4%)	1 (25%) (neg 1; pos 0)	1 (33%); (neg 1; pos 0)	2 (100%) (neg 1; pos 1)		
	Multiplex	0	18 (25%) (neg 4; pos 14)	4 (44.4%) (neg 4; pos 0)	2 (50%) (neg 2; pos 0)	0	1 (50%) (neg 0; pos 1)		
	Not performed	19 (73.1%)	3 (4.2%)	5 (63.6%)	0	2 (66.7%)	0		

J Investig Allergol Clin Immunol 2023; Vol. 33(6) doi: 10.18176/jiaci.0912

DATE (YEAR) OF ALLERGY ASSESSMENT 2014 (2) 2015 (2) 2016 (2) 2017 (3) 2018 (1) 2019 (1) 2021 (4)	2012 (2) 2013 (15) 2014 (8) 2015 (6) 2016 (6) 2017 (11) 2018 (5) 2019 (6) 2020 (1) 2021 (10)	2013 (1) 2014 (2) 2015 (2) 2016 (1) 2019 (2) 2021 (1)	2013 (1) 2016 (1) 2019 (2)	2012 (1) 2013 (1) 2016 (1)	2014 (1) 2019 (1)	
--	---	--	----------------------------------	----------------------------------	----------------------	--

